---
title: 'Manufacturing Daily Summary: What Happened on November 13, 2026'
headline: Lilly breaks ground on $3.5 billion Pennsylvania plant
description: The facility is expected to make obesity medicines, including investigational
  retatrutide, and begin operating by 2031.
url: https://thebench.bio/news/manufacturing/2026-11-13
topic: manufacturing
date: '2026-11-13'
covers:
- '2026-11-13'
date_published: '2026-11-14T00:02:55Z'
date_modified: '2026-11-14T00:02:55Z'
tags:
- Manufacturing
sources: 2
publisher: TheBench.Bio
---

# Manufacturing Daily Summary: What Happened on November 13, 2026

**Lilly breaks ground on $3.5 billion Pennsylvania plant**

The facility is expected to make obesity medicines, including investigational retatrutide, and begin operating by 2031.

## Today in brief

Eli Lilly began building a $3.5 billion manufacturing facility in the Lehigh Valley, Pennsylvania. [1] [2] Lilly expects the site to create about 850 jobs and support roughly 2,000 construction workers. [1] [2]

## Lilly’s plant is planned for newer injectable medicines

Lilly expects the facility to make newer obesity medicines, including retatrutide, which remains investigational and is in Phase 3 trials. [1] [2] The company expects the site to begin operating by 2031. [1]

Lilly says the facility will use machine learning, digitally integrated systems and advanced data analytics. [2] The project is part of a broader U.S. manufacturing investment that Lilly puts at $50 billion since 2020. [1] [2]

## The day in numbers

- **$3.5 billion**: Lilly’s planned investment in the Lehigh Valley facility. [1] [2]
- **2031**: Year Lilly expects the facility to begin operating. [1]
- **850**: Jobs Lilly expects the facility to create. [1] [2]
- **2,000**: Construction workers expected to be supported during the build. [1] [2]

## Also published

- [Automating the journey from bench to bedside](<https://www.pharmaceuticalprocessingworld.com/automating-the-journey-from-bench-to-bedside/>), Pharmaceutical Processing World
- [What 3 Principles Guide Merck's Biologics and ADC Capacity Placement?](<https://www.biopharminternational.com/view/principles-guide-merck-biologics-adc-capacity-placement>), BioPharm International
- [Downstream Processing: Purifying Complex Antibody Therapeutics When Target Molecules Misbehave](<https://www.genengnews.com/multimedia/webinars/downstream-processing-purifying-complex-antibody-therapeutics-when-target-molecules-misbehave/>), GEN
- [Advancing Pressure Protection in Biopharma: How Integrated Bypass Technology Elevates Single-Use Pump Design](<https://www.drugdiscoverytrends.com/advancing-pressure-protection-in-biopharma-how-integrated-bypass-technology-elevates-single-use-pump-design/>), Drug Discovery and Development

## Sources

1. [Eli Lilly Breaks Ground on $3.5 billion Pennsylvania Manufacturing Site](<https://www.pharmexec.com/view/eli-lilly-breaks-ground-3-billion-pennsylvania-manufacturing-site>), Pharmaceutical Executive, 2026-11-13
2. [Lilly breaks ground on $3.5bn manufacturing site in Pennsylvania](<https://www.bioprocessintl.com/facilities-capacity/lilly-breaks-ground-on-3-5bn-manufacturing-site-in-pennsylvania>), BioProcess International, 2026-11-13

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.pharmexec.com/view/eli-lilly-breaks-ground-3-billion-pennsylvania-manufacturing-site>
[2]: <https://www.bioprocessintl.com/facilities-capacity/lilly-breaks-ground-on-3-5bn-manufacturing-site-in-pennsylvania>
